Upgrade of recommended nuclear cross section data base for production of therapeutic radionuclides

Tárkányi, F.; Hermanne, Alex; Ignatyuk, A. V.; Takács, S.; Capote, R.

doi:10.1007/s10967-022-08189-1

Cited by 11 publications

(6 citation statements)

References 105 publications

(205 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is evident that those two evaluations are not fully supported by the new data. In particular the updated curve (Tárkányi et al, 2022) appears to be too low. Considering all the data published we conclude that a new evaluation is necessary using the theoryassisted selection of data.…”

Section: Therapeutic Radionuclide 67 Cumentioning

confidence: 95%

See 1 more Smart Citation

Copper radionuclides for theranostic applications: towards standardisation of their nuclear data. A mini-review

Hussain,

Qaim,

Spahn

et al. 2023

Front. Chem.

View full text Add to dashboard Cite

Copper has several clinically relevant radioisotopes and versatile coordination chemistry, allowing attachment of its radionuclides to biological molecules. This characteristic makes it suitable for applications in molecular imaging or radionuclide targeted therapy. Of particular interest in nuclear medicine today is the theranostic approach. This brief review considers five radionuclides of copper. These are Cu-60, Cu-61, Cu-62, Cu-64, and Cu-67. The first four are positron emitters for imaging, and the last one Cu-67 is a β–-emitting radionuclide suitable for targeted therapy. The emphasis here is on theory-aided evaluation of available experimental data with a view to establishing standardised cross-section database for production of the relevant radionuclide in high purity. Evaluated cross section data of the positron emitters have been already extensively reported; so here they are only briefly reviewed. More attention is given to the data of the 68Zn(p,2p)67Cu intermediate energy reaction which is rather commonly used for production of 67Cu.

show abstract

Section: Therapeutic Radionuclide 67 Cumentioning

confidence: 95%

“…The standardisation of production cross sections was attempted under an IAEA-CRP (Qaim et al, 2011). Another IAEA-CRP version has also been presented (Tárkányi et al, 2022). Jung et al (2023) reported extensive new cross-section measurements in the higher energy range.…”

Section: Therapeutic Radionuclide 67 Cumentioning

confidence: 99%

Copper radionuclides for theranostic applications: towards standardisation of their nuclear data. A mini-review

Hussain,

Qaim,

Spahn

et al. 2023

Front. Chem.

View full text Add to dashboard Cite

show abstract

“… Comprehensive presentation of experimental data and TENDL predictions for the 103 Rh(p,n) 103 Pd reaction [ 25 ] (with permission). …”

Section: Methodsmentioning

confidence: 99%

Innovative Approach to Producing Palladium-103 for Auger-Emitting Radionuclide Therapy: A Proof-of-Concept Study

Laouameria,

Hunyadi,

Csík

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

Auger-emitting radionuclides, exemplified by Pd-103, exhibit considerable therapeutic potential in cancer treatment due to their high cytotoxicity and localized biological impact. Despite these advantages, the separation of such radionuclides presents a complicated challenge, requiring intricate and time-intensive “wet chemistry” methods attributed to the exceptional chemical inertness of the associated metals. This study proposes an innovative solution to this separation challenge through the design and implementation of a piece of radionuclide separation equipment (RSE). The equipment employs a dry distillation approach, capitalizing on differences in partial vapor pressures between irradiated and resulting radioactive metals, with a diffusion-driven extraction method applied to separate Pd-103 radionuclides generated via the proton irradiation of Rh-103 at cyclotron. Our optimization endeavors focused on determining the optimal temperature for effective metal separation and adjusting the diffusion, evaporation, and deposition rates, as well as addressing chemical impurities. The calculations indicate 17% ± 2% separation efficiency with our RSE. Approximately 77 ± 2% and 49 ± 2% of the deposited Pd-103 were isolated on substrates of Nb foil and ZnO-covered W disc, respectively. The proposed innovative dry distillation method that has been experimentally tested offers a promising alternative to conventional separation techniques, enabling enhanced purity and cost-efficient cancer treatment strategies.

show abstract

“…The relative intensities were obtained as a weighted average of values from about 107 individual measurements. For example, the measured I(rel) values for one of the strongest 656.008-keV  ray range between 63(8) and 87 (8), relative to I(rel) = 100 for the 282.956-keV  ray, with a reported weighted average value of I(rel) = 79.3 (10) (see Table 3 and Ref. [20]).…”

Section: Review Of Decay Data For 61 Cu Fg Kondevmentioning

confidence: 99%

Summary Report of the Technical Meeting on Nuclear Data for Medical Applications

Eagle,

Hermanne,

Nichols

et al. 2024

View full text Add to dashboard Cite

A summary is given of an IAEA Technical Meeting on Nuclear Data for Medical Applications at which participants assessed present and future medical applications for many radionuclides based upon their existing and potential diagnostic and therapeutic properties. Debate focused upon charged-particle induced reactions and their production cross sections, derivation of optimal yields, minimisation of radionuclidic impurities, decay-data requirements, and nuclear data requirements for proton and heavy-ion radiotherapy. Technical discussions are included in this report, along with comprehensive listings and detailed recommendations for future measurements. Subsequent excitation functions and decay-data evaluations will also be needed to ensure the necessary quality and consistency of the datasets to be assembled in an existing dedicated IAEA-NDS database that is regularly maintained and supported.

show abstract

Upgrade of recommended nuclear cross section data base for production of therapeutic radionuclides

Cited by 11 publications

References 105 publications

Copper radionuclides for theranostic applications: towards standardisation of their nuclear data. A mini-review

Copper radionuclides for theranostic applications: towards standardisation of their nuclear data. A mini-review

Innovative Approach to Producing Palladium-103 for Auger-Emitting Radionuclide Therapy: A Proof-of-Concept Study

Summary Report of the Technical Meeting on Nuclear Data for Medical Applications

Contact Info

Product

Resources

About